{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:24:18Z","timestamp":1788200658439,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T00:00:00Z","timestamp":1585785600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30EY014801"],"award-info":[{"award-number":["P30EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology Case Reports"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.ajoc.2020.100691","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T17:43:27Z","timestamp":1586281407000},"page":"100691","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer"],"prefix":"10.1016","volume":"18","author":[{"given":"Christopher R.","family":"Dermarkarian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimesh A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor M.","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. William","family":"Harbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.ajoc.2020.100691_bib1","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jamaoncol.2015.1184","article-title":"Efficacy and safety of nivolumab in patients with BRAF V600 Mutant and BRAF-wild-type Advanced melanoma: a pooled analysis of 4 clinical trials","volume":"1","author":"Larken","year":"2015","journal-title":"JAMA Oncology"},{"issue":"18","key":"10.1016\/j.ajoc.2020.100691_bib2","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (Anti-Programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100691_bib3","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","article-title":"Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation","volume":"35","author":"Nguyen","year":"2016","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100691_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100691_bib5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/CJI.0b013e318247a4e7","article-title":"PD-1 blockage augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancer","volume":"35","author":"Dulos","year":"2011","journal-title":"J Immunother"},{"issue":"6","key":"10.1016\/j.ajoc.2020.100691_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","article-title":"Th17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1","volume":"13","author":"Amadi-Obi","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100691_bib7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.39406","article-title":"Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment","volume":"68","author":"de Velasco","year":"2016","journal-title":"Arthritis Rheum"},{"issue":"26","key":"10.1016\/j.ajoc.2020.100691_bib8","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajoc.2020.100691_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/857519","article-title":"Immune-medicated averse events associated with ipilimumab CTLA-4 blockage therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100691_bib10","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation \u2013 a case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"10.1016\/j.ajoc.2020.100691_bib11","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajoc.2020.100691_bib12","first-page":"1183","article-title":"Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report","volume":"10","author":"Richardson","year":"2017","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajoc.2020.100691_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s12886-017-0611-3","article-title":"Bilateral uveitis and macular edema induced by Nivolumab: a case report","volume":"17","author":"Theillac","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100691_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/09273948.2016.1215473","article-title":"Bilateral anterior uveitis associated with Nivolumab therapy","volume":"26","author":"Karlin","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"8","key":"10.1016\/j.ajoc.2020.100691_bib15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1346-8138.13612","article-title":"Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient,","volume":"44","author":"Arai","year":"2017","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.ajoc.2020.100691_bib16","article-title":"Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma","volume":"3","author":"Baughman","year":"2017","journal-title":"Med Case Rep (Wilmington)."},{"issue":"11","key":"10.1016\/j.ajoc.2020.100691_bib17","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jiac.2017.04.007","article-title":"Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient","volume":"23","author":"Kanno","year":"2017","journal-title":"J Infect Chemother"},{"issue":"4","key":"10.1016\/j.ajoc.2020.100691_bib18","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0002-9394(00)00659-0","article-title":"Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel","volume":"130","author":"Jabs","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100691_bib19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1869-5760-3-43","article-title":"Drug-induced uveitis","volume":"3","author":"London","year":"2013","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ajoc.2020.100691_bib20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0039-6257(97)00130-6","article-title":"Drug-induced uveitis","volume":"42","author":"Moorthy","year":"1998","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100691_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/09273948.2011.644383","article-title":"Drug-induced inflammation in patients on TNF\u03b1 inhibitors","volume":"20","author":"Cunningham","year":"2012","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajoc.2020.100691_bib22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3109\/09273948.2010.531176","article-title":"TNF inhibitors for uveitis: balancing efficacy and safety","volume":"18","author":"Cunningham","year":"2010","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajoc.2020.100691_bib23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ajoc.2020.100691_bib24","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/ICU.0000000000000530","article-title":"Drug-induced uveitis","volume":"29","author":"Moorthy","year":"2018","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100691_bib25","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/j.jfo.2018.02.001","article-title":"Bilateral uveitis associated with nivolumab therapy","volume":"41","author":"Remond","year":"2018","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.ajoc.2020.100691_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ajoc.2018.02.005","article-title":"Combination nivolumab- and cabir- alizumab-associated acute bilateral anterior and posterior scleritis and ante- rior uveitis","volume":"10","author":"Gonzales","year":"2018","journal-title":"Am J Ophthalmol Case Rep"},{"key":"10.1016\/j.ajoc.2020.100691_bib27","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ccr3.911","article-title":"Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma","volume":"5","author":"Matsuo","year":"2017","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.ajoc.2020.100691_bib28","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00417-017-3835-2","article-title":"Checkpoint inhibitor-induced uveitis: a case series","volume":"256","author":"Conrady","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajoc.2020.100691_bib29","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/1346-8138.14273","article-title":"HLA-DRB1 04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib\/trametinib therapy","volume":"45","author":"Fujimura","year":"2018","journal-title":"J Dermatol"},{"key":"10.1016\/j.ajoc.2020.100691_bib30","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"}],"container-title":["American Journal of Ophthalmology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993618301154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451993618301154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T14:59:20Z","timestamp":1762527560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451993618301154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":30,"alternative-id":["S2451993618301154"],"URL":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100691","relation":{},"ISSN":["2451-9936"],"issn-type":[{"value":"2451-9936","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bilateral uveitis associated with nivolumab therapy for metastatic non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajoc.2020.100691","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100691"}}